Oxbryta Prior Authorization Criteria Updates Scheduled for April 5

Date: March 10, 2022 Attention: Primary care providers Effective Date: April 5, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.Call to action:  On April 5, 2022, HHSC will revise the prior authorization criteria in the Sickle Cell Disease Agents clinical prior authorization for Oxbryta (voxelotor) to ensure alignment with the U. S. Food and Drug Administration-approved indications and package inserts. How this impacts providers: The criteria update includes the FDA’s recent age expansion to 4 years and older, and the removal of criteria step relating to the drug interaction with CYP3A4 inhibitors or fluconazole. Updated prior authorization criteria can be found on Navitus. Next steps for providers: Prescribers should adjust their prescribing patterns accordingly and share this update with their staff as well If you have any questions, please email Provider Network Management at: providerrelations@texaschildrens.org.For access to all provider alerts,log into: www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.